https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Tue, 07 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe The VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiencyi,ii VARIPULSE Pro to be featured at EHRA 2026 alongside VARIPURE 12-month interim data Tue, 07 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe https://www.jnj.com/media-center/press-releases/inlexzo-gemcitabine-intravesical-system-assigned-permanent-billing-code-supporting-access-for-patients-with-certain-bladder-cancers · INLEXZO permanent J-code (J9183) effective April 1 Wed, 01 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/inlexzo-gemcitabine-intravesical-system-assigned-permanent-billing-code-supporting-access-for-patients-with-certain-bladder-cancers https://www.jnj.com/media-center/press-releases/stemi-dtu-randomized-control-trial-demonstrates-for-the-first-time-that-a-combination-of-delayed-reperfusion-and-left-ventricular-unloading-does-not-increase-myocardial-infarct-size Sat, 28 Mar 2026 16:08:06 GMT https://www.jnj.com/media-center/press-releases/stemi-dtu-randomized-control-trial-demonstrates-for-the-first-time-that-a-combination-of-delayed-reperfusion-and-left-ventricular-unloading-does-not-increase-myocardial-infarct-size https://www.jnj.com/media-center/press-releases/icotyde-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-once-daily-pill-for-plaque-psoriasis Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD study Sat, 28 Mar 2026 14:33:53 GMT https://www.jnj.com/media-center/press-releases/icotyde-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-once-daily-pill-for-plaque-psoriasis https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatment Wed, 18 Mar 2026 12:04:56 GMT https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer · Data presented at EAU 2026 show an 89 percent complete response rate in intermediate‑risk disease with durable responses observed over 18 months and tolerable safety profile · Erda-iDRS has the potential to be the first targeted treatment for early‑stage bladder cancer Fri, 13 Mar 2026 16:46:47 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients • 97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL1 • 97% of patients would recommend this IOL to friends or family2 • TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL1* Thu, 12 Mar 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients https://www.jnj.com/media-center/press-releases/tecvayli-teclistamab-monotherapy-application-submitted-to-the-ema-for-relapsed-refractory-multiple-myeloma-after-at-least-one-prior-therapy Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free survival and overall survival versus standard of care, reducing the risk of disease progression or death by 71% in a high unmet need patient population2 Tue, 10 Mar 2026 11:55:05 GMT https://www.jnj.com/media-center/press-releases/tecvayli-teclistamab-monotherapy-application-submitted-to-the-ema-for-relapsed-refractory-multiple-myeloma-after-at-least-one-prior-therapy https://www.jnj.com/media-center/press-releases/european-commission-approves-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-brca1-2-mutated-metastatic-hormone-sensitive-prostate-cancer-mhspc Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard of care1 Approximately one in ten patients with mHSPC harbour BRCA1/2 alterations, reinforcing the need for new targeted treatment options2 Expanded indication for niraparib and abiraterone acetate delivers a precision-based treatment approach for this patient population1 Mon, 09 Mar 2026 17:01:55 GMT https://www.jnj.com/media-center/press-releases/european-commission-approves-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-brca1-2-mutated-metastatic-hormone-sensitive-prostate-cancer-mhspc https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit Thu, 05 Mar 2026 20:30:20 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line https://www.jnj.com/media-center/press-releases/johnson-johnson-therapy-nipocalimab-granted-u-s-fda-fast-track-designation-in-systemic-lupus-erythematosus-sle Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus Tue, 03 Mar 2026 13:05:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-therapy-nipocalimab-granted-u-s-fda-fast-track-designation-in-systemic-lupus-erythematosus-sle https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-2026 Mon, 02 Mar 2026 21:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-2026 https://www.jnj.com/media-center/press-releases/early-study-results-from-johnson-johnson-show-promising-antitumor-activity-with-combination-of-pasritamig-and-docetaxel-in-advanced-prostate-cancer Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer Thu, 26 Feb 2026 19:30:00 GMT https://www.jnj.com/media-center/press-releases/early-study-results-from-johnson-johnson-show-promising-antitumor-activity-with-combination-of-pasritamig-and-docetaxel-in-advanced-prostate-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-catheter-portfolio-with-launch-of-cereglide-42-cereglide-57-and-innerglide-7 CEREGLIDE™ 42 and 57 provide physicians with a versatile multi-axial system and simplified workflowi New devices support system compatibility, aspiration force, and delivery to distal* targets as part of company’s effort to elevate ischemic stroke care Thu, 26 Feb 2026 12:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-catheter-portfolio-with-launch-of-cereglide-42-cereglide-57-and-innerglide-7 https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-fda-approval-of-imaavy-nipocalimab-aahu-as-the-first-ever-fda-approved-treatment-for-warm-autoimmune-hemolytic-anemia-waiha Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood cells, leading to debilitating anemia Tue, 24 Feb 2026 21:12:10 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-fda-approval-of-imaavy-nipocalimab-aahu-as-the-first-ever-fda-approved-treatment-for-warm-autoimmune-hemolytic-anemia-waiha https://www.jnj.com/media-center/press-releases/subcutaneous-rybrevant-amivantamab-approved-by-european-commission-for-every-three-week-and-every-four-week-dosing-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 Mon, 23 Feb 2026 16:17:41 GMT https://www.jnj.com/media-center/press-releases/subcutaneous-rybrevant-amivantamab-approved-by-european-commission-for-every-three-week-and-every-four-week-dosing-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-long-term-data-show-sustained-clinical-and-endoscopic-remission-in-ulcerative-colitis-through-3-years More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients 78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement) Sat, 21 Feb 2026 13:00:00 GMT https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-long-term-data-show-sustained-clinical-and-endoscopic-remission-in-ulcerative-colitis-through-3-years https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of care Thu, 19 Feb 2026 22:00:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-footprint-with-more-than-1-billion-investment-in-next-generation-cell-therapy-manufacturing-facility-in-pennsylvania • Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company’s portfolio of transformational medicines • Facility will boost Pennsylvania’s economy by creating more than 4,000 construction jobs and 500 biomanufacturing jobs, while further strengthening the Company’s annual $10 billion economic impact across the state • Investment is part of Company’s $55 billion U.S. investment by early 2029 and supports plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S. Wed, 18 Feb 2026 15:15:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-footprint-with-more-than-1-billion-investment-in-next-generation-cell-therapy-manufacturing-facility-in-pennsylvania https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-breakthrough-therapy-designation-for-patients-with-advanced-head-and-neck-cancer New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer Wed, 18 Feb 2026 12:41:20 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-breakthrough-therapy-designation-for-patients-with-advanced-head-and-neck-cancer https://www.jnj.com/media-center/press-releases/fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-the-only-egfr-targeted-therapy-that-can-be-administered-once-a-month Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6 Tue, 17 Feb 2026 13:00:00 GMT https://www.jnj.com/media-center/press-releases/fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-the-only-egfr-targeted-therapy-that-can-be-administered-once-a-month https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-barclays-28th-annual-global-healthcare-conference Mon, 09 Feb 2026 21:16:51 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-barclays-28th-annual-global-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-early-outcomes-from-the-omny-af-pilot-study-at-2026-af-symposium OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsi Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platformii,iii,iv,v Sat, 07 Feb 2026 00:00:08 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-early-outcomes-from-the-omny-af-pilot-study-at-2026-af-symposium https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-new-scientific-evidence-and-reinforces-its-leadership-with-portfolio-advancements-at-af-symposium Accepted abstracts include a Late Breaker presentation of the OMNY-AF Pilot and real-world safety and efficiency data for the VARIPULSE Platform Introduction of the VARIPULSE Plus Platform reinforces Johnson & Johnson’s commitment to continued innovation Tue, 03 Feb 2026 13:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-new-scientific-evidence-and-reinforces-its-leadership-with-portfolio-advancements-at-af-symposium https://www.jnj.com/media-center/press-releases/johnson-johnson-releases-report-on-surgeon-burnout-as-more-than-40-surveyed-consider-leaving-the-profession Survey of more than 1,500 surgeons across five countries assesses the impact of administrative burden and moral fatigue on burnout More than half of surgeons surveyed report feeling burned out Respondents look to mentorship, flexible support models, and technology to address the strain Tue, 03 Feb 2026 13:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-releases-report-on-surgeon-burnout-as-more-than-40-surveyed-consider-leaving-the-profession